Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. The phase 2 trial demonstrated that tirzepatide, in varying dosages, successfully met the primary endpoint, with a substantial percentage of participants achieving MASH resolution without worsening fibrosis after […]